Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Gurney

Showing results (1-10 of 135) with videos related to

Pageof 14
Sort By:
British Journal of Cancer|April 16, 2002
How to calculate the dose of chemotherapyHoward Gurney
Future Oncology (London, England)|February 21, 2018
Nivolumab in the treatment of advanced renal cell carcinomaMalmaruha Arasaratnam, Howard Gurney
The Prostate|June 27, 2017
Dose considerations for anti-cancer drugs in metastatic prostate cancerMegan Crumbaker, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|July 18, 2019
Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancerLoma Al-Mansouri, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|April 23, 2014
Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancerPhillip Parente, Francis Parnis, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|February 29, 2012
Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspectivePhillip Parente, Francis Parnis, Howard Gurney
European Journal of Hospital Pharmacy : Science and Practice|February 20, 2021
Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?Loma Al-Mansouri, Malmaruha Arasaratnam, Howard Gurney
Expert Opinion on Drug Metabolism & Toxicology|September 19, 2008
Dose calculation of anticancer drugsBo Gao, Heinz-Josef Klumpen, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|April 10, 2015
Clinical perspectives: practical insights from clinical experience with cabazitaxel in AustraliaPhillip Parente, Howard Gurney, Siobhan Ng, et al.
Case Reports in Oncology|November 13, 2023
Case Series: "Silent" Spinal Epidural Metastases in Metastatic Castrate-Resistant Prostate CancerDhanusha Sabanathan, Andrew O Parsonson, John J Park, et al.
Pageof 14

Showing results (1-10 of 135) with videos related to

Sort By:
Pageof 14
British Journal of Cancer|April 16, 2002
How to calculate the dose of chemotherapyHoward Gurney
Future Oncology (London, England)|February 21, 2018
Nivolumab in the treatment of advanced renal cell carcinomaMalmaruha Arasaratnam, Howard Gurney
The Prostate|June 27, 2017
Dose considerations for anti-cancer drugs in metastatic prostate cancerMegan Crumbaker, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|July 18, 2019
Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancerLoma Al-Mansouri, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|April 23, 2014
Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancerPhillip Parente, Francis Parnis, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|February 29, 2012
Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspectivePhillip Parente, Francis Parnis, Howard Gurney
European Journal of Hospital Pharmacy : Science and Practice|February 20, 2021
Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?Loma Al-Mansouri, Malmaruha Arasaratnam, Howard Gurney
Expert Opinion on Drug Metabolism & Toxicology|September 19, 2008
Dose calculation of anticancer drugsBo Gao, Heinz-Josef Klumpen, Howard Gurney
Asia-Pacific Journal of Clinical Oncology|April 10, 2015
Clinical perspectives: practical insights from clinical experience with cabazitaxel in AustraliaPhillip Parente, Howard Gurney, Siobhan Ng, et al.
Case Reports in Oncology|November 13, 2023
Case Series: "Silent" Spinal Epidural Metastases in Metastatic Castrate-Resistant Prostate CancerDhanusha Sabanathan, Andrew O Parsonson, John J Park, et al.
Pageof 14